Gastrointestinal Cancer News

Patients newly diagnosed with cancer and considered to be of high socioeconomic status had the highest use of telemedicine in the early days of the COVID-19 pandemic, according to a research letter published in JAMA Oncology.

The FDA granted orphan drug designation to two investigational T-cell immunotherapies for the treatment of advanced hepatocellular carcinoma.

The FDA has granted investigational device exemption to medical diagnostics company Check-Cap for a two-part pivotal study to evaluate C-Scan, a new screening test that detects precancerous polyps.

The FDA cleared investigational new drug applications for three cell therapies in development for oncology indications.

American Association for Cancer Research released a first-of-its-kind report detailing the impact of the COVID-19 pandemic on the cancer community, both in patient care and research practice.

First-line treatment with nivolumab in patients with advanced esophageal squamous cell carcinoma resulted in longer overall survival compared with chemotherapy treatment alone, according to research.

Cancer cell-derived or allergic reaction-released histamine dampened antitumor immunity and conferred resistance to cancer immunotherapy, according to a retrospective study published in Cancer Cell.

Patients with cancer had few differences in reported adverse events compared with people without cancer after receiving COVID-19 vaccines, according to study results published in JNCCN — Journal of the National Comprehensive Cancer Network.

Germline microRNA-based biomarkers accurately predicted grade 2 or higher immune-related adverse events associated with anti-PD-1/PD-L1 therapy among patients with various cancer types, according to study results.

A culturally tailored patient navigation program improved colorectal cancer screening rates and reduced the gender gap in screenings among Hispanic patients, according to results published in Cancer.